Last edited by Dagar
Wednesday, July 15, 2020 | History

4 edition of Minimal residual disease in acute leukemia found in the catalog.

Minimal residual disease in acute leukemia

  • 395 Want to read
  • 18 Currently reading

Published by M. Nijhoff Publishers, Distributors for the U.S. and Canada, Kluwer Boston in Boston, Hingham, MA, USA .
Written in English

    Subjects:
  • Acute leukemia -- Treatment.,
  • Leukemia in children -- Treatment.,
  • Leukemia -- Diagnosis.,
  • Leukemia -- Therapy.,
  • Neoplasm recurrence, Local -- Diagnosis.,
  • Neoplasm recurrence, Local -- Therapy.,
  • Bone marrow -- Transplantation.

  • Edition Notes

    Includes bibliographies and index.

    Statementedited by B. Löwenberg, A. Hagenbeek.
    SeriesDevelopments in oncology ;, 19
    ContributionsLöwenberg, B. 1946-, Hagenbeek, A.
    Classifications
    LC ClassificationsRC643 .M53 1984
    The Physical Object
    Paginationxiii, 401 p. :
    Number of Pages401
    ID Numbers
    Open LibraryOL3184750M
    ISBN 100898386306
    LC Control Number83027562

      In patients with AML who achieve a complete remission (CR), the minimal/measurable residual disease (MRD) is a well-recognized risk factor for relapse, which can be considered a broad predictive biomarker useful to guide the patient’s management and a potential surrogate endpoint for relapse-free survival (RFS) in clinical trials [4,5].   Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A et al () Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association by: 2.

    Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. Background: Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of .

    Background: Several studies have shown that detection of minimal residual disease (MRD) in acute myeloid leukemia (AML) is an independent prognostic factor. This study aimed to evaluate the significance of dynamic MRD pretransplantation on outcome of AML patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).   The identification of residual leukemia following therapy, termed minimal or measurable residual disease (MRD), has emerged as one of the most important prognostic factors for patients with acute leukemia, including acute myeloid leukemia (AML).Author: Brent L. Wood.


Share this book
You might also like
European financial integration and its implications for the United States.

European financial integration and its implications for the United States.

Historical Trends Of Tuna Catches In The World (Fao Fisheries Technical Paper)

Historical Trends Of Tuna Catches In The World (Fao Fisheries Technical Paper)

Developing Reading Skills

Developing Reading Skills

Takeovers and shareholders

Takeovers and shareholders

creed

creed

evolution of harmony

evolution of harmony

Policy on quality assurance

Policy on quality assurance

All the material facts in the history of epidemic cholera

All the material facts in the history of epidemic cholera

Keys to the kingdom

Keys to the kingdom

Surprise Present

Surprise Present

The biggest apple ever

The biggest apple ever

model of control on construction sites.

model of control on construction sites.

Mothers images of motherhood

Mothers images of motherhood

Minimal residual disease in acute leukemia Download PDF EPUB FB2

Comprehensive and innovative, Leukemia and Lymphoma: Detection of Minimal Residual Disease sets the stage for implementing the new standard detection and quantitation techniques as reliable tools for clinical decision-making, as well as for improved predictions and treatment : $6.

Search within book. Front Matter. Pages i-xiii. PDF. Detection of Minimal Residual Disease in Acute Leukemia. Nucleic Acid Cytometry, Interphase Chromosomes and Nucleolar Antigen in the Detection of Residual Leukemia in Morphologic Remission.

Barlogie, W. Hittelman, F. Davis, H. Kantarjian. 'Minimal Residual Disease in Acute Leukemia: ' summarizes the fast advancements in this area. Several disciplines are concerned with the analysis of leukemic cells.

The perspectives of cytogenetic and molecular genetic approaches for applica­ tion in the detection of MRD are reviewed. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay, Leukemia, 12 Author: Guido Marcucci, Michael A.

Caligiuri. increasingly evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes.

Assays based on polymerase chain reaction or flow cytometry can detect one ALLCited by: Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

J Clin Oncol. ; 6. Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid. We studied the impact of minimal residual disease (MRD)- and graft-vs.-host disease (GvHD)-guided multiple consolidation chemotherapy and donor lymphocyte infusions (DLIs) to prevent second relapse in patients with acute leukemia relapsing post-transplant and who achieved complete remission after induction chemotherapy and DLI.

Three independent studies published ten years ago conclusively demonstrated that minimal residual disease (MRD) is a powerful prognostic indicator in newly diagnosed childhood acute lymphoblastic leukemia (ALL).1–3These studies represented the culmination of efforts of many investigators (reviewed in 4), and stimulated the design of treatment protocols in which risk.

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL ): a randomised controlled trial.

Over the last decade (), application of minimal residual disease (MRD) diagnostics in acute lymphoblastic leukemia (ALL) has expanded significantly from a limited number of study groups in Europe and the United States to worldwide application. Currently, virtually all pediatric ALL patients and a large part of adult ALL cases in Western countries are being monitored with MRD Cited by:   Minimal residual disease (MRD) after therapy has unequivocal prognostic value in acute leukemia.

Over the past 20 years, a number of techniques have evolved into routine laboratory tools to detect MRD, most notably, multiparametric flow cytometry (MFC) and quantitative polymerase chain reaction (PCR)-based molecular methods. Detection of Early Relapse and Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia by Enumeration of Terminal Deoxynucleotidyl Transferase-Positive Cells in Peripheral Blood.

Pages Buchanan, George R. (et al.). Objective: To investigate the prognostic significance of detection of minimal residual disease after first induction treatment (MRD(1)) in adult acute lymphoblastic leukemia (ALL) patients treated with autologous stem cell transplantation (auto-HSCT).Methods: The clinical data of 87 ALL patients who underwent auto-HSCT during February to April with MRD(1) detection data by flow.

Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatment of 'minimal residual disease' (MRD). These investigations are conducted with the common objective to tackle the remaining cells. 'Minimal Residual Disease in Acute Leukemia: ' summarizes the fast advancements in this area.

Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults.

This book addresses all. In adult acute lymphoblastic leukemia (ALL) the complete remission (CR) rates have improved to 85% to 90%. Despite this high CR rate, 40% to 50% of patients eventually relapse.

1 This occurs because of the limited sensitivity of cytomorphology in assessing complete molecular remission. Thus, more sensitive methods that detect leukemic cells on a molecular level and identify minimal residual Cited by: 9. Buy Leukemia and Lymphoma: Detection of Minimal Residual Disease: Read Kindle Store Reviews - Leukemia and Lymphoma: Detection of Minimal Residual Disease - Kindle edition by Theodore F.

Zipf, Dennis A. Johnston. Pediatric Inspired regimens (PIRs) in Adolescents and Young Adults (AYA) with ALL have led to better long-term outcomes. In Latin America, the AYA pop. L protocol for adult patients with acute lymphoblastic leukemia: a protocol utilizing prognostic factors, intensive chemotherapy and autologus "purged" marrow transplantation to eradicate minimal residual disease.- Treatment of minimal residual disease in adult ALL: the German national study Abstract.

Response to induction therapy is a powerful prognostic indicator in acute myeloid leukemia (AML). Measurable/minimal residual disease (MRD) assays ar. Minimal residual disease and acute myeloid leukemia In AML patients, morphologic assessment is performed to evaluate chemotherapy response and to define remission status.

By definition, patients are in CR when less than 5% blast cells are present in the bone marrow (BM) concurrent with evidence of normal erythropoiesis, granulopoiesis and Cited by: 1.1 day ago  3. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

J Clin Oncol. ;– 4. Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML. Minimal residual disease in acute myelogenous leukemia. Int J Lab Hematol.

;39(suppl 1)– 5.[Minimal residual disease before post-remission therapy predicts outcomes in younger adult with intermediate-risk acute myeloid leukemia] Zhonghua Xue Ye Xue Za Zhi. Feb 14;40(2) doi: /